BIO-TECHNE Corp Form 4 August 22, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL OMB

3235-0287 Number: January 31,

Expires: 2005

Estimated average burden hours per

response... 0.5

if no longer subject to Section 16. Form 4 or

Check this box

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Middle)

(Zip)

1(b).

(Last)

(City)

(Instr. 3)

(Print or Type Responses)

1. Name and Address of Reporting Person * Furlow Brenda S.

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

BIO-TECHNE Corp [TECH]

(Check all applicable)

614 MCKINLEY PLACE NE

(First)

3. Date of Earliest Transaction (Month/Day/Year)

below)

Director 10% Owner X_ Officer (give title Other (specify

08/18/2016

below) SVP - General Counsel

(Street) 4. If Amendment, Date Original

(Month/Day/Year)

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line) _X_ Form filed by One Reporting Person

Form filed by More than One Reporting

D

Person

MINNEAPOLIS, MN 55413

(State)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of Securities Beneficially Owned Following

6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)

Reported Transaction(s)

or (D) Price

(A)

Code V Amount

(Instr. 3 and 4)

Common Stock

1,946 (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(9-02)

Edgar Filing: BIO-TECHNE Corp - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed or (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day	Date	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 94.35					(2)	08/12/2021	Common Stock	15,000
Stock Option (Right to Buy)	\$ 108.49					(3)	08/07/2022	Common Stock	10,000
Stock Option (Right to Buy)	\$ 108.49					(5)	08/07/2022	Common Stock	7,500
Restricted Stock Units	<u>(4)</u>					(5)	<u>(5)</u>	Common Stock	1,200
Stock Option (Right to Buy)	\$ 106.59	08/18/2016		A	14,476	<u>(6)</u>	08/18/2023	Common Stock	14,476
Stock Option (Right to Buy)	\$ 106.59	08/18/2016		A	10,857	<u>(7)</u>	08/18/2023	Common Stock	10,857
Restricted Stock Units	<u>(4)</u>	08/18/2016		A	1,759	<u>(7)</u>	<u>(7)</u>	Common Stock	1,759

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Furlow Brenda S.							
614 MCKINLEY PLACE NE			SVP - General Counsel				
MINNEAPOLIS MN 55413							

Reporting Owners 2

Signatures

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed.

08/22/2016

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 834 shares of restricted stock units that vest on 7/1/17.
- (2) 3,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.
- (3) 2,500 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- (4) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (5) Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (6) Vests 3,619 shares on each of 8/18/17, 8/18/18, 8/18/19 and 8/18/20.
- (7) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3